Physician profile
Anees Afroze
NPI 1043352057
$6,176.03
in general payments reported to CMS, 2019-2025
35 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $123 · 2021: $116 · 2022: $137 · 2023: $362 · 2024: $3,869 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,869 · Education: $1,520 · Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,868.73 |
| Education | $1,520.00 |
| Food and Beverage | $1,262.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,535.74 | 2023-2024 | |
| Glaxosmithkline, LLC. | $342.77 | 2019-2024 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $301.41 | 2019-2024 | Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.98 | 2019-2024 | Ofev |
| Genentech USA, INC. | $240.97 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $117.48 | 2019 | |
| Chiesi USA, INC. | $116.02 | 2021 | |
| Insmed, INC. | $109.64 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $105.14 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Abbvie INC. | $93.83 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.10 | 2019-2025 | Dupixent |
| Noah Medical Corporation | $81.87 | 2025 | Galaxy |
| Mylan Specialty L.P. | $72.09 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $67.15 | 2019-2024 | Uptravi, Opsumit |
| Ambu INC. | $65.83 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $62.95 | 2024-2025 | Tyvaso |
| Jazz Pharmaceuticals INC. | $59.60 | 2024-2025 | |
| Csl Behring | $52.20 | 2024 | Kcentra |
| Circassia INC. | $43.30 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $39.16 | 2022-2023 | Purified Cortrophin Gel |
| Genzyme Corporation | $39.16 | 2025 | |
| Philips North America LLC | $36.51 | 2023-2025 | Vest Therapy Und |
| Mallinckrodt Hospital Products INC. | $35.20 | 2023-2024 | Acthar |
| Astellas Pharma US INC | $32.07 | 2019 | |
| Allergan, INC. | $25.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.75 | 2025 | Zerbaxa |
| Baxter Healthcare | $20.61 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Boston Scientific Corporation | $19.82 | 2023 | Ams 800 Artificial Urinary Sphincter |
| Idorsia Pharmaceuticals US INC | $19.71 | 2024 | Quviviq |
| Gilead Sciences, INC. | $18.24 | 2025 | |
| Amgen INC. | $14.91 | 2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $14.29 | 2019 | |
| Electromed, INC. | $14.06 | 2023 | Smartvest |
| Pulmonx Corporation | $13.37 | 2022 | |
| Pfizer INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anees Afroze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.